Adjuvant Chemotherapy for Pancreatic Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (30 October 2023) | Viewed by 3090
Special Issue Editor
Special Issue Information
Dear Colleagues,
Pancreatic ductal adenocarcinoma (PDAC) is one of the major causes of cancer-related mortality worldwide. Although curative resection is desired for long-term survival rates from PDAC, even after surgery, survival rates remain low. To improve prognosis after surgery, adjuvant chemotherapy is mandatory. There are several treatment ways available, such as S1, gemcitabine, gemcitabine + capecitabine, gemcitabine + nab-paclitaxel and FOLFIRINOX. However, there is insufficient evidence regarding the selection of drugs and optimal duration of adjuvant chemotherapy. Furthermore, in addition to tools which are available now, diagnostic methods for detection of recurrence are required. Liquid biopsy and circ RNAs may be able to detect recurrence at an earlier stage. In this Special Issue on “Adjuvant Chemotherapy for Pancreatic Cancer”, recent advances in adjuvant chemotherapy are discussed.
Prof. Dr. Keiichi Kubota
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pancreatic ductal adenocarcinoma
- adjuvant chemotherapy
- pancreatic resection
- neoadjuvant chemotherapy
- hyperthermia
- curative resection
- recurrence
- S1
- gemcitabine
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
